Penumbra, Inc. Reports Third Quarter 2022 Financial Results
Penumbras, Inc. (NYSE: PEN) announced a 12.4% increase in third-quarter revenue, totaling $213.7 million, compared to $190.1 million in Q3 2021. Revenue from vascular products rose by 17.0% to $123.4 million, while neuro product sales increased by 6.7% to $90.3 million. Gross profit was $135.3 million with a gross margin of 63.3%. The company updated its 2022 revenue guidance to $840-$845 million, reflecting 12-13% growth. Despite strong performance, the Lightning Flash product launch is delayed to Q1 2023, impacting short-term revenue expectations.
- Revenue increased by 12.4% to $213.7 million compared to Q3 2021.
- Gross profit improved to $135.3 million, with a gross margin of 63.3%.
- Strong revenue growth in vascular products (+17.0%).
- 2022 revenue guidance revised to $840-$845 million, indicating 12-13% growth.
- Lightning Flash product launch delayed to Q1 2023, impacting near-term revenue.
- Operating expenses increased to $129.9 million, or 60.8% of total revenue.
ALAMEDA, Calif., Nov. 3, 2022 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the third quarter ended September 30, 2022.
- Revenue of
$213.7 million in the third quarter of 2022, an increase of12.4% , or15.1% in constant currency1, compared to the third quarter of 2021.
Third Quarter 2022 Financial Results
Total revenue increased to
Gross profit was
Total operating expenses were
Income from operations for the third quarter of 2022 was
Updated Full Year 2022 Financial Outlook
Notwithstanding a strong start to the fourth quarter, the Company is updating its 2022 revenue guidance to account for two, near-term dynamics: the Lightning Flash product launch is now expected to occur in the first quarter of 2023, six weeks later than the previous mid-fourth quarter 2022 estimate, and an incremental headwind of
Webcast and Conference Call Information
Penumbra, Inc. will host a conference call to discuss the third quarter 2022 financial results after market close on Thursday, November 3, 2022 at 4:30 PM Eastern Time. The conference call can be accessed live over the phone by dialing (888) 330-2443 for domestic and international callers (conference id: 4604622), or the webcast can be accessed on the "Events" section under the "Investors" tab of the Company's website at: www.penumbrainc.com. The webcast will be available on the Company's website for at least two weeks following the completion of the call.
About Penumbra
Penumbra, Inc., headquartered in Alameda, California, is a global healthcare company focused on innovative therapies. Penumbra designs, develops, manufactures and markets novel products and has a broad portfolio that addresses challenging medical conditions in markets with significant unmet need. Penumbra supports healthcare providers, hospitals and clinics in more than 100 countries. For more information, visit www.penumbrainc.com and connect on Twitter and LinkedIn.
______________________________ |
1See "Non-GAAP Financial Measures" for important information about our use of non-GAAP measures. |
Non-GAAP Financial Measures
In addition to financial measures prepared in accordance with U.S. generally accepted accounting principles ("GAAP"), the Company uses the following non-GAAP financial measures in this press release: a) constant currency and b) non-GAAP operating expenses, non-GAAP income from operations, non-GAAP net income and non-GAAP diluted earnings per share ("EPS").
Constant Currency. The Company's constant currency revenue disclosures estimate the impact of changes in foreign currency rates on the translation of the Company's current period revenue as compared to the applicable comparable period in the prior year. This impact is derived by taking the current local currency revenue and translating it into U.S. dollars based upon the foreign currency exchange rates used to translate the local currency revenue for the applicable comparable period in the prior year, rather than the actual exchange rates in effect during the current period. It does not include any other effect of changes in foreign currency rates on the Company's results or business.
Non-GAAP operating expenses, non-GAAP income from operations, non-GAAP net income and non-GAAP diluted EPS. The adjustments to the GAAP financial measures reflect the exclusion of:
- the effect of the amortization of finite lived intangible assets acquired in connection with the Sixense acquisition over their estimated useful lives; and
- the tax deficiencies or excess tax benefits associated with share-based compensation arrangements.
Full reconciliation of these non-GAAP measures to the most comparable GAAP measures is set forth in the tables below.
Our management believes the non-GAAP financial measures disclosed in this press release are useful to investors in assessing the operating performance of our business and provide meaningful comparisons to prior periods and thus a more complete understanding of our business than could be obtained absent this disclosure. Specifically, we consider the change in constant currency revenue as a useful metric as it provides an alternative framework for assessing how our underlying business performed excluding the effect of foreign currency rate fluctuations. We consider non-GAAP operating expenses, non-GAAP income from operations, non-GAAP net income and non-GAAP diluted EPS useful metrics as they provide an alternative framework for assessing how our underlying business performed excluding the amortization expense of finite lived intangible assets acquired in connection with the Sixense acquisition and the tax deficiencies or excess tax benefits associated with share-based compensation arrangements.
The non-GAAP financial measures included in this press release may be different from, and therefore may not be comparable to, similarly titled measures used by other companies. These non-GAAP measures should not be considered in isolation or as alternatives to GAAP measures. We urge investors to review the reconciliation of these non-GAAP financial measures to the comparable GAAP financial measures included in this press release, and not to rely on any single financial measure to evaluate our business.
Forward-Looking Statements
Except for historical information, certain statements in this press release are forward-looking in nature and are subject to risks, uncertainties and assumptions about us. Our business and operations are subject to a variety of risks and uncertainties and, consequently, actual results may differ materially from those projected by any forward-looking statements. Factors that could cause actual results to differ from those projected include, but are not limited to: the impact of the COVID-19 pandemic on our business, results of operations and financial condition; failure to sustain or grow profitability or generate positive cash flows; failure to effectively introduce and market new products; delays in product introductions; significant competition; inability to further penetrate our current customer base, expand our user base and increase the frequency of use of our products by our customers; inability to achieve or maintain satisfactory pricing and margins; manufacturing difficulties; permanent write-downs or write-offs of our inventory; product defects or failures; unfavorable outcomes in clinical trials; inability to maintain our culture as we grow; fluctuations in foreign currency exchange rates; potential adverse regulatory actions; and the potential impact of any acquisitions, mergers, dispositions, joint ventures or investments we may make. These risks and uncertainties, as well as others, are discussed in greater detail in our filings with the Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K for the year ended December 31, 2021 filed with the SEC on February 22, 2022. There may be additional risks of which we are not presently aware or that we currently believe are immaterial which could have an adverse impact on our business. Any forward-looking statements are based on our current expectations, estimates and assumptions regarding future events and are applicable only as of the dates of such statements. We make no commitment to revise or update any forward-looking statements in order to reflect events or circumstances that may change.
Penumbra, Inc. Condensed Consolidated Balance Sheets (unaudited) (in thousands) | ||||
September 30, 2022 | December 31, 2021 | |||
Assets | ||||
Current assets: | ||||
Cash and cash equivalents | $ 54,844 | $ 59,379 | ||
Marketable investments | 129,583 | 195,496 | ||
Accounts receivable, net | 189,006 | 133,940 | ||
Inventories | 320,304 | 263,504 | ||
Prepaid expenses and other current assets | 29,888 | 29,155 | ||
Total current assets | 723,625 | 681,474 | ||
Property and equipment, net | 64,082 | 58,856 | ||
Operating lease right-of-use assets | 174,684 | 131,955 | ||
Finance lease right-of-use assets | 34,114 | 36,276 | ||
Intangible assets, net | 83,360 | 90,618 | ||
Goodwill | 165,426 | 166,388 | ||
Deferred taxes | 62,827 | 65,698 | ||
Other non-current assets | 13,483 | 12,985 | ||
Total assets | $ 1,321,601 | $ 1,244,250 | ||
Liabilities and Stockholders' Equity | ||||
Current liabilities: | ||||
Accounts payable | $ 25,365 | $ 13,421 | ||
Accrued liabilities | 101,672 | 99,796 | ||
Current operating lease liabilities | 9,417 | 8,267 | ||
Current finance lease liabilities | 1,878 | 1,713 | ||
Total current liabilities | 138,332 | 123,197 | ||
Non-current operating lease liabilities | 180,897 | 137,045 | ||
Non-current finance lease liabilities | 25,325 | 26,523 | ||
Other non-current liabilities | 3,295 | 3,558 | ||
Total liabilities | 347,849 | 290,323 | ||
Stockholders' equity: | ||||
Common stock | 38 | 37 | ||
Additional paid-in capital | 947,040 | 910,614 | ||
Accumulated other comprehensive loss | (13,353) | (2,630) | ||
Retained earnings | 40,027 | 45,906 | ||
Total stockholders' equity | 973,752 | 953,927 | ||
Total liabilities and stockholders' equity | $ 1,321,601 | $ 1,244,250 | ||
Penumbra, Inc. Condensed Consolidated Statements of Operations (unaudited) (in thousands, except share and per share amounts) | ||||||||
Three Months Ended September 30, | Nine Months Ended September 30, | |||||||
2022 | 2021 | 2022 | 2021 | |||||
Revenue | $ 213,678 | $ 190,117 | $ 625,917 | $ 543,579 | ||||
Cost of revenue | 78,351 | 70,205 | 229,137 | 193,644 | ||||
Gross profit | 135,327 | 119,912 | 396,780 | 349,935 | ||||
Operating expenses: | ||||||||
Research and development | 21,320 | 16,734 | 61,443 | 52,548 | ||||
Sales, general and administrative | 108,573 | 94,397 | 334,088 | 264,831 | ||||
Total operating expenses | 129,893 | 111,131 | 395,531 | 317,379 | ||||
Income from operations | 5,434 | 8,781 | 1,249 | 32,556 | ||||
Interest (expense) income, net | (43) | 138 | (162) | 917 | ||||
Other expense, net | (2,356) | (1,137) | (4,323) | (3,021) | ||||
Income (loss) before income taxes | 3,035 | 7,782 | (3,236) | 30,452 | ||||
Provision for (benefit from) income taxes | 5,306 | (249) | 2,643 | 3,196 | ||||
Consolidated net (loss) income | $ (2,271) | $ 8,031 | $ (5,879) | $ 27,256 | ||||
Net loss attributable to non-controlling interest | — | (819) | — | (2,661) | ||||
Net (loss) income attributable to Penumbra, Inc. | $ (2,271) | $ 8,850 | $ (5,879) | $ 29,917 | ||||
Net (loss) income attributable to Penumbra, Inc. per share: | ||||||||
Basic | $ (0.06) | $ 0.24 | $ (0.16) | $ 0.82 | ||||
Diluted | $ (0.06) | $ 0.24 | $ (0.16) | $ 0.80 | ||||
Weighted average shares outstanding: | ||||||||
Basic | 37,918,452 | 36,617,961 | 37,778,362 | 36,532,822 | ||||
Diluted | 37,918,452 | 37,611,355 | 37,778,362 | 37,592,095 | ||||
Penumbra, Inc. Reconciliation of GAAP Operating Expenses and GAAP Income from Operations to Non-GAAP Operating Expenses and Non-GAAP (unaudited) (in thousands) | ||||||||
Three Months Ended September 30, | Nine Months Ended September 30, | |||||||
2022 | 2021 | 2022 | 2021 | |||||
GAAP operating expenses | $ 129,893 | $ 111,131 | $ 395,531 | $ 317,379 | ||||
GAAP total operating expenses includes the effect of the following items: | ||||||||
Amortization of finite lived intangible assets acquired2 | 2,380 | — | 5,949 | — | ||||
Non-GAAP operating expenses | $ 127,513 | $ 111,131 | $ 389,582 | $ 317,379 | ||||
GAAP income from operations | $ 5,434 | $ 8,781 | $ 1,249 | $ 32,556 | ||||
GAAP income from operations includes the effect of the following items: | ||||||||
Amortization of finite lived intangible assets acquired | 2,380 | — | 5,949 | — | ||||
Non-GAAP income from operations | $ 7,814 | $ 8,781 | $ 7,198 | $ 32,556 | ||||
______________________________ |
1See "Non-GAAP Financial Measures" for important information about our use of non-GAAP measures. |
2The amortization expense includes |
Penumbra, Inc. Reconciliation of GAAP Net (Loss) Income and GAAP Diluted EPS to Non-GAAP Net Income and Non-GAAP Diluted EPS1 (unaudited) (in thousands, except share and per share amounts) | ||||||||||||||||
Three Months Ended September 30, 2022 | Three Months Ended September 30, 2021 | Nine Months Ended | Nine Months Ended | |||||||||||||
Net (loss) | Diluted | Net | Diluted | Net (loss) | Diluted | Net | Diluted | |||||||||
GAAP net (loss) income | $ (2,271) | $ (0.06) | $ 8,850 | $ 0.24 | $ (5,879) | $ (0.16) | $ 29,917 | $ 0.80 | ||||||||
GAAP net (loss) income includes the effect of the | ||||||||||||||||
Amortization of finite lived intangible assets acquired | 2,380 | 0.06 | — | — | 5,949 | 0.16 | — | — | ||||||||
Tax effect on the non-GAAP adjustments above2 | (554) | (0.01) | — | — | (1,386) | (0.04) | — | — | ||||||||
Tax deficiencies (excess tax benefits) related to | 722 | 0.02 | (4,244) | (0.12) | 1,666 | 0.05 | (7,431) | (0.20) | ||||||||
Non-GAAP net income | $ 277 | $ 0.01 | $ 4,606 | $ 0.12 | $ 350 | $ 0.01 | $ 22,486 | $ 0.60 | ||||||||
Weighted average shares outstanding used to compute: | ||||||||||||||||
GAAP diluted EPS | 37,918,452 | 37,611,355 | 37,778,362 | 37,592,095 | ||||||||||||
Non-GAAP diluted EPS3 | 38,762,786 | 37,611,355 | 38,743,727 | 37,592,095 | ||||||||||||
______________________________ |
1See "Non-GAAP Financial Measures" for important information about our use of non-GAAP measures. |
2For the three and nine months ended September 30, 2022, management used a combined federal and state tax rate of |
3For the purposes of calculating Non-GAAP diluted EPS for the three and nine months ended September 30, 2022, non-GAAP diluted weighted average shares outstanding of 38,762,786 and 38,743,727, respectively, were used, as the Company had non-GAAP net income in the period. |
Penumbra, Inc. Reconciliation of Revenue Growth by Geographic Regions to Constant Currency Revenue Growth1 (unaudited) (in thousands, except for percentages) | ||||||||||||||
Three Months Ended September 30, | Reported Change | FX Impact | Constant Currency Change | |||||||||||
2022 | 2021 | $ | % | $ | $ | % | ||||||||
United States | $ 148,819 | $ 134,834 | $ 13,985 | 10.4 % | $ — | $ 13,985 | 10.4 % | |||||||
International | 64,859 | 55,283 | 9,576 | 17.3 % | 5,224 | 14,800 | 26.8 % | |||||||
Total | $ 213,678 | $ 190,117 | $ 23,561 | 12.4 % | $ 5,224 | $ 28,785 | 15.1 % | |||||||
Nine Months Ended September 30, | Reported Change | FX Impact | Constant Currency Change | |||||||||||
2022 | 2021 | $ | % | $ | $ | % | ||||||||
United States | $ 434,583 | $ 383,306 | $ 51,277 | 13.4 % | $ — | $ 51,277 | 13.4 % | |||||||
International | 191,334 | 160,273 | 31,061 | 19.4 % | 11,614 | 42,675 | 26.6 % | |||||||
Total | $ 625,917 | $ 543,579 | $ 82,338 | 15.1 % | $ 11,614 | $ 93,952 | 17.3 % | |||||||
Penumbra, Inc. Reconciliation of Revenue Growth by Product Categories to Constant Currency Revenue Growth1 (unaudited) (in thousands, except for percentages) | ||||||||||||||
Three Months Ended September 30, | Reported Change | FX Impact | Constant Currency Change | |||||||||||
2022 | 2021 | $ | % | $ | $ | % | ||||||||
Vascular | $ 123,361 | $ 105,465 | $ 17,896 | 17.0 % | $ 1,974 | $ 19,870 | 18.8 % | |||||||
Neuro | 90,317 | 84,652 | 5,665 | 6.7 % | 3,250 | 8,915 | 10.5 % | |||||||
Total | $ 213,678 | $ 190,117 | $ 23,561 | 12.4 % | $ 5,224 | $ 28,785 | 15.1 % | |||||||
Nine Months Ended September 30, | Reported Change | FX Impact | Constant Currency Change | |||||||||||
2022 | 2021 | $ | % | $ | $ | % | ||||||||
Vascular | $ 369,712 | $ 295,314 | $ 74,398 | 25.2 % | $ 4,733 | $ 79,131 | 26.8 % | |||||||
Neuro | 256,205 | 248,265 | 7,940 | 3.2 % | 6,881 | 14,821 | 6.0 % | |||||||
Total | $ 625,917 | $ 543,579 | $ 82,338 | 15.1 % | $ 11,614 | $ 93,952 | 17.3 % | |||||||
______________________________ |
1See "Non-GAAP Financial Measures" for important information about our use of non-GAAP measures. |
Investor Relations
Penumbra, Inc.
510-995-2461
investors@penumbrainc.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/penumbra-inc-reports-third-quarter-2022-financial-results-301668247.html
SOURCE Penumbra, Inc.
FAQ
What were Penumbra's Q3 2022 financial results?
What is Penumbra's updated revenue guidance for 2022?
When is the Lightning Flash product launch scheduled?
How much did Penumbra's operating expenses increase in Q3 2022?
What was Penumbra's gross profit margin in Q3 2022?
